X-Linked Dystonia ParkinsonismNCT05592028
High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism
A study testing transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy in people with X-Linked Dystonia Parkinsonism, run by University of the Philippines Manila - Philippine General Hospital at 1 site in Philippines.
Trial summary
X-linked dystonia-parkinsonism (XDP) is a rare, X-linked, adult-onset, and progressive movement disorder seen almost exclusively in men from Panay Island in the Philippines. The disease is associated with mutations involving the DYT3/TAF1 gene, and all the cases described so far have been linked to Filipino ancestry. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- X-Linked Dystonia Parkinsonism
- What is being tested?
- transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy
- Type of treatment
- Medical device
- How many people
- Not given
- Where
- 1 sitePhilippines
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years old and above
- have been diagnosed with XDP and confirmed by genetic testing
- have a skull density ratio (SDR) of >/= 0.35 on CT scan
- have psychiatric and medical clearance
- have passed the neurocognitive test
- have undergone MRgFUS pallidothalamic tractomy, either unilateral or bilateral,
Who cannot join
- patients aged less than 18 years old
- patients who have movement disorders other than XDP
- patients with abnormal neuroimaging findings that would preclude MRgFUS lesioning
- Skull SDR < 0.35
- patients with medical contraindications
- patients who did not fulfill the inclusion criteria
Trial locations and contacts
1 site in 1 country.
Philippines1 site
- Available
Philippine General Hospital
Manila, 1000
Roland Dominic G Jamora, MD, PhD, +63 2 85242338, rgjamora@up.edu.ph
Kathleen Joy O Khu, MD, +63 2 85242338, kokhu@up.edu.ph
About this study
Official title: Bilateral Transcranial Magnetic Resonance-guided Focused Ultrasound Pallidothalamic Tractotomy for Patients With X-linked Dystonia-parkinsonism
X-linked dystonia-parkinsonism (XDP) is a rare, X-linked, adult-onset, and progressive movement disorder seen almost exclusively in men from Panay Island in the Philippines. The disease is associated with mutations involving the DYT3/TAF1 gene, and all the cases described so far have been linked to Filipino ancestry. Although XDP is very rare globally, the prevalence is 5.74 per 100,000 individuals in Panay Island and 0.31 per 100,000 in the Philippines as a whole. Majority of patients (95%) were males, and the mean age of onset was 39 years. The mean duration of illness was 16 years, and the mean age of death was 55.6 years.
Read the detailed description
To determine the outcomes of MRgFUS pallidothalamic tractotomy on adult XDP patients at the Philippine General Hospital.
This is a prospective study that aims to determine the outcomes of MRgFUS pallidothalamic tractotomy (both unilateral and bilateral) on adult XDP patients at the Philippine General Hospital.
No sample size will be determined a priori. The study will be conducted over a period of five years, and all eligible patients may be invited to join the study during this period.
The procedure will be performed inside the MRI suite, using a 1.5 Tesla MRI system (GE Optima MR450, USA) and the ExAblate Neuro device (InSightec, Haifa, Israel) to deliver the focused ultrasound. The patient's head will be shaved and immobilized using a stereotactic frame under local anesthesia. An elastic diaphragm will be attached to the patient's head and connected to the ultrasound transducer,8 and the patient will be positioned inside the bore of the MRI. A reference MRI scan will be performed to position the transducer to the target, after which the MRI images (T1-weighted axial and T2-weighted axial/coronal MRI at 1 mm slices) will be fused to the preoperative CT scan for the skull-correction algorithm.8 Stereotactic treatment planning will then be performed to target the pallidothalamic tract. It is usually located at the midcommisural line (0 to 1.0 mm posterior) in the anterior-posterior direction, 8-10 mm lateral to the intercommisural line in the mediolateral direction, 0-1.5 mm inferior to the intercommisural line in the dorsoventral direction, and 6.5-7.5 mm to the thalamo-ventricular border.7 The lesion will be made 3 mm lateral to the mamillo-thalamic tract and superior and medial to the medial subthalamic nucleus.9,11,12 Once the target is set, a series of low-power sonications producing temperatures between 40-45oC and lasting 10-20 seconds will be performed.8 Clinical assessment for tremor suppression and treatment side effects will be made after each sonication,8 and definitive non-reversible thermal ablation will be performed only at the setting wherein the patient experiences tremor reduction or suppression with no adverse effects.9 The final sonication temperature usually ranges between 55-63oC.8 After the treatment, the stereotactic frame will be removed and the patient will be monitored in the hospital overnight.
The patients will be assessed within 24 hours of treatment then asked to follow up with the movement disorder neurologist (RDJ) at 2 weeks, 3 months, 6 months, 9 months, and 12 months post-treatment through a clinic visit. Video recording will be taken on initial visit and at each follow up visit. Another blinded assessor will score the videos of the patients. The outcome will be assessed using the XDP-Movement Disorder Society of the Philippines (XDP-MDSP) Scale at each visit, and comparing it to the pre-treatment baseline, as well as using the XDP Clinical and Functional Staging. The pre- and post-treatment BFMDRS and UPDRS scores will also be obtained.
For bilateral MRgFUS tractotomy, the contralateral lesion will be done at least 6 months after the first procedure, provided that there are no serious adverse effects from the first PTT lesioning.
Demographic, clinical, treatment-related, and outcome data of all study patients will be collected prospectively by the investigators throughout the duration of the study.
- Conditions
- X-Linked Dystonia Parkinsonism
- Being tested
- transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy
- Keywords
- High intensity focused ultrasound, pallidothalamic tractotomy, transcranial MR-guided focused ultrasound
- Medical subject headings
- Dystonia 3, Torsion, X-Linked
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomyDevice
XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for X-Linked Dystonia ParkinsonismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- University of the Philippines Manila - Philippine General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Roland Dominic G. Jamora, University of the Philippines Manila - Philippine General Hospital
- Investigators
- Roland Dominic G Jamora, MD, PhD, Principal investigator, Department of Neurosciences, University of the Philippines Manila
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05592028
- Sponsor's protocol ID
- DoN-001
- Status last verified
- Aug 2022
- First submitted
- 21 Aug 2022
- Last updated
- 24 Oct 2022
- Results posted
- No
Publications
Jamora RDG, Khu KJO, Sy MCC, Pascual JSG, Legaspi GD, Aguilar JA. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol. BMC Neurol. 2023 Aug 18;23(1):306. doi: 10.1186/s12883-023-03344-x.
PubMed 37596524
Study at a glance
From the registry record, last updated by the sponsor on 24 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bilateral Transcranial Magnetic Resonance-guided Focused Ultrasound Pallidothalamic Tractotomy for Patients With X-linked Dystonia-parkinsonism
- ClinicalTrials.gov ID
- NCT05592028
- Acronym / sponsor ID
- DoN-001
- Conditions
- X-Linked Dystonia Parkinsonism
- Keywords
- High intensity focused ultrasound, pallidothalamic tractotomy, transcranial MR-guided focused ultrasound
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- University of the Philippines Manila - Philippine General HospitalUniversity, hospital or other
- First posted
- 24 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
X-linked dystonia-parkinsonism (XDP) is a rare, X-linked, adult-onset, and progressive movement disorder seen almost exclusively in men from Panay Island in the Philippines. The disease is associated with mutations involving the DYT3/TAF1 gene, and all the cases described so far have been linked to Filipino ancestry. Although XDP is very rare globally, the prevalence is 5.74 per 100,000 individuals in Panay Island and 0.31 per 100,000 in the Philippines as a whole. Majority of patients (95%) were males, and the mean age of onset was 39 years. The mean duration of illness was 16 years, and the mean age of death was 55.6 years.
Detailed description
To determine the outcomes of MRgFUS pallidothalamic tractotomy on adult XDP patients at the Philippine General Hospital.
This is a prospective study that aims to determine the outcomes of MRgFUS pallidothalamic tractotomy (both unilateral and bilateral) on adult XDP patients at the Philippine General Hospital.
No sample size will be determined a priori. The study will be conducted over a period of five years, and all eligible patients may be invited to join the study during this period.
The procedure will be performed inside the MRI suite, using a 1.5 Tesla MRI system (GE Optima MR450, USA) and the ExAblate Neuro device (InSightec, Haifa, Israel) to deliver the focused ultrasound. The patient's head will be shaved and immobilized using a stereotactic frame under local anesthesia. An elastic diaphragm will be attached to the patient's head and connected to the ultrasound transducer,8 and the patient will be positioned inside the bore of the MRI. A reference MRI scan will be performed to position the transducer to the target, after which the MRI images (T1-weighted axial and T2-weighted axial/coronal MRI at 1 mm slices) will be fused to the preoperative CT scan for the skull-correction algorithm.8 Stereotactic treatment planning will then be performed to target the pallidothalamic tract. It is usually located at the midcommisural line (0 to 1.0 mm posterior) in the anterior-posterior direction, 8-10 mm lateral to the intercommisural line in the mediolateral direction, 0-1.5 mm inferior to the intercommisural line in the dorsoventral direction, and 6.5-7.5 mm to the thalamo-ventricular border.7 The lesion will be made 3 mm lateral to the mamillo-thalamic tract and superior and medial to the medial subthalamic nucleus.9,11,12 Once the target is set, a series of low-power sonications producing temperatures between 40-45oC and lasting 10-20 seconds will be performed.8 Clinical assessment for tremor suppression and treatment side effects will be made after each sonication,8 and definitive non-reversible thermal ablation will be performed only at the setting wherein the patient experiences tremor reduction or suppression with no adverse effects.9 The final sonication temperature usually ranges between 55-63oC.8 After the treatment, the stereotactic frame will be removed and the patient will be monitored in the hospital overnight.
The patients will be assessed within 24 hours of treatment then asked to follow up with the movement disorder neurologist (RDJ) at 2 weeks, 3 months, 6 months, 9 months, and 12 months post-treatment through a clinic visit. Video recording will be taken on initial visit and at each follow up visit. Another blinded assessor will score the videos of the patients. The outcome will be assessed using the XDP-Movement Disorder Society of the Philippines (XDP-MDSP) Scale at each visit, and comparing it to the pre-treatment baseline, as well as using the XDP Clinical and Functional Staging. The pre- and post-treatment BFMDRS and UPDRS scores will also be obtained.
For bilateral MRgFUS tractotomy, the contralateral lesion will be done at least 6 months after the first procedure, provided that there are no serious adverse effects from the first PTT lesioning.
Demographic, clinical, treatment-related, and outcome data of all study patients will be collected prospectively by the investigators throughout the duration of the study.
Study design
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 18 years old and above
- have been diagnosed with XDP and confirmed by genetic testing
- have a skull density ratio (SDR) of >/= 0.35 on CT scan
- have psychiatric and medical clearance
- have passed the neurocognitive test
Key exclusion criteria (6 listed)
- patients aged less than 18 years old
- patients who have movement disorders other than XDP
- patients with abnormal neuroimaging findings that would preclude MRgFUS lesioning
- Skull SDR < 0.35
- patients with medical contraindications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomyXDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy. | Device | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Oct 2022.
- Derived from this study: PubMed 37596524Jamora RDG, Khu KJO, Sy MCC, Pascual JSG, Legaspi GD, Aguilar JA. Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol. BMC Neurol. 2023 Aug 18;23(1):306. doi: 10.1186/s12883-023-03344-x.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Roland Dominic G Jamora, MD, PhD principal investigator
Department of Neurosciences, University of the Philippines Manila
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy in people with X-Linked Dystonia Parkinsonism, run by University of the Philippines Manila - Philippine General Hospital at 1 site in Philippines.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 24 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Philippines. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Roland Dominic G Jamora, MD, PhD (+63 2 85242338, rgjamora@up.edu.ph), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05592028, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2022.